Trial Profile
Phase 2 Multicenter, Double-Blind, Placebo Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects With Pulmonary Arterial Hypertension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2020
Price :
$35
*
At a glance
- Drugs IMR-261 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms PRIMEx
- Sponsors Complexa
- 21 Oct 2020 Rationale and Design of the Primex Trial presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
- 12 Aug 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Jul 2020 Status changed from recruiting to active, no longer recruiting.